Scientists probe why interferon works for some blood cancer patients but not others
NCT ID NCT05850273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to understand exactly how the drug interferon attacks cancer stem cells in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze blood samples from 80 adults to see why some patients respond well while others do not. The goal is to improve treatment and predict who will benefit most from interferon therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inserm U1287
RECRUITINGVillejuif, Île-de-France Region, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Could muscle loss predict blood cancer outcomes?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?